Carvedilol vs. Metoprolol Succinate for Heart Failure with ICD
This study, called CARVTOP-ICD, is comparing two common heart medications, carvedilol and metoprolol succinate, in people with heart failure with reduced ejection fraction (HFrEF) who also have an implantable cardioverter defibrillator (ICD). An ICD is a small device placed in your chest to help regulate your heartbeat and prevent sudden cardiac death. The study wants to see if one medication is better at preventing events like needing ICD therapy, being hospitalized for heart problems, or cardiovascular death. You could join if you are 18 or older, have an ICD for HFrEF, and are currently taking metoprolol succinate but are willing to switch to carvedilol. The study aims to enroll 2,000 participants and will follow them for up to 3 years.
- Study design
- This is a randomized study, meaning you would be assigned by chance to either continue metoprolol succinate or switch to carvedilol. It is an open-label study, so both you and your doctor will know which medication you are taking. The study plans to include 2,000 participants.
- What's involved
- You would be followed for up to 3 years, with regular check-ups that include looking at your ICD, checking how well you're taking your medication, and asking about your quality of life.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 3 years to track the first occurrence of ICD therapy, cardiovascular hospitalization, or cardiovascular death.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
At a glance
Conditions
NCT06964464
Where you'd take part
This study runs at 13 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
AdventHealth Redmond
Rome, Georgiastudy coordinator listed
Recruiting
AdventHealth Shawnee Mission
Shawnee Mission, Kansasstudy coordinator listed
Recruiting
CHRISTUS Trinity Mother Frances Health System
Tyler, Texasstudy coordinator listed
Recruiting
Creighton University Medical Center
Omaha, Nebraskastudy coordinator listed
Recruiting
Health University of Utah
Salt Lake City, Utahstudy coordinator listed
Recruiting
Henry Ford Health System
Detroit, Michiganstudy coordinator listed
Recruiting
HonorHealth
Scottsdale, Arizonastudy coordinator listed
Recruiting
New York-Presbyterian Brooklyn Methodist Hospital
Brooklyn, New Yorkstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Composite Endpoint: First Occurrence of ICD Therapy, Cardiovascular Hospitalization, or Cardiovascular DeathUp to 3 years
This composite outcome measures the time to first occurrence of one of the following events: (1) ICD therapy (appropriate or inappropriate shocks or anti-tachycardia pacing), (2) hospitalization due to cardiovascular causes, or (3) cardiovascular death. Only the first event occurring during the study period will be counted per participant.